STOCK TITAN

Iovance Biotherp - IOVA STOCK NEWS

Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.

Iovance Biotherapeutics (IOVA) pioneers tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers, leading the next generation of personalized immunotherapies. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.

Access timely announcements including FDA submissions, clinical trial data publications, manufacturing advancements, and partnership agreements. Our curated collection ensures you stay informed about IOVA developments impacting oncology treatment paradigms and biopharmaceutical innovation.

Key updates cover therapy approvals, research collaborations, financial results, and scientific presentations. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Iovance's latest progress in developing TIL-based therapies for melanoma, cervical cancer, and other solid tumors. Regularly updated to serve as your definitive resource for IOVA-related news analysis.

Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announces senior leadership's participation in upcoming healthcare conferences. The company will present at TD Cowen's, Barclays', and H.C. Wainwright's events to discuss novel polyclonal TIL therapies for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the successful U.S. launch of Amtagvi™, the first and only one-time, individualized T cell therapy for solid tumor cancer. The company also reports progress in regulatory submissions for Amtagvi in the European Union, United Kingdom, and Canada. Fourth quarter and full year 2023 financial results and corporate updates were shared, highlighting healthy demand and momentum for Amtagvi.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (IOVA) will announce its Q4 and full-year 2023 financial results on February 28, 2024. The company focuses on developing TIL therapies for cancer patients. A conference call and webcast will discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences earnings
Rhea-AI Summary
WuXi Advanced Therapies Receives FDA Approval for AMTAGVI, a One-Time T Cell Therapy for Solid Tumor Cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the pricing of an underwritten offering of 23,014,000 shares of its common stock at $9.15 per share, aiming to raise approximately $211 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for new employees. The options cover 40,450 shares with an exercise price of $9.87 per share, vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
none
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces FDA approval for novel polyclonal TIL therapies for cancer patients. The company will host a conference call and live webcast to discuss the approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
conferences
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (IOVA) receives FDA approval for AMTAGVI, a groundbreaking T cell therapy for advanced melanoma. AMTAGVI is the first individualized T cell therapy for solid tumor cancer, offering hope to patients with limited treatment options. The therapy deploys patient-specific TIL cells to fight cancer, achieving deep and durable responses in clinical trials. The approval is based on safety and efficacy results from the C-144-01 trial, with 31.5% of patients achieving an objective response. AMTAGVI is manufactured at the Iovance Cell Therapy Center in Philadelphia and must be administered in Authorized Treatment Centers (ATCs). Iovance is dedicated to providing access to AMTAGVI for patients with advanced melanoma through a comprehensive support program, IovanceCares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for six new non-executive employees, covering 51,375 shares of common stock. The options were granted under the 2021 Inducement Plan, with an exercise price of $7.94 and vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
none
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial due to a recently reported Grade 5 serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. This has no impact on other Iovance clinical trials and is independent of the FDA’s Priority Review of the biologics license application (BLA) for lifileucel in advanced melanoma. Preliminary data for IOV-LUN-202 was reported in July 2023, showing ongoing responses and duration of response greater than six months for 71% of the confirmed responders in the trial. The BLA remains on track toward the PDUFA action date of February 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.67%
Tags
none
Iovance Biotherp

Nasdaq:IOVA

IOVA Rankings

IOVA Stock Data

1.00B
279.26M
0.62%
84.02%
18.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS